Subscribe
Share
Share
Embed
A niacin trial shows 82% glioblastoma survival; Saputo launches an ingredients division; omega-3 aids ADHD cognition; mulberry reshapes gut bacteria.
A striking vitamin B3 trial and Saputo's new whey ingredients division are reshaping how health brands think about niacin, protein supply, and differentiation. Here's what marketers need to know today.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four strong stories on the agenda today.
Klara: We're opening with a small but striking vitamin B3 trial in glioblastoma patients — and what it actually means for supplement marketers.
Marco: Then omega-3 and ADHD in children — a big meta-analysis with some nuance worth unpacking.
Klara: Mulberry makes a surprise entrance in the gut health space.
Marco: And Saputo is restructuring around protein. Let's get into it.
Marco: A small clinical trial is putting vitamin B3 back on the radar — this time in the context of one of the most aggressive brain cancers we know.
Marco: Glioblastoma kills most patients within 15 months of diagnosis. Standard treatment — surgery, radiotherapy, chemotherapy — gives people more time, but rarely enough. Researchers have been searching for anything that improves those odds. High-dose vitamins have entered that conversation seriously in the last few years, partly driven by promising Vitamin C trial data.
Marco: Now B3 — niacin, a vitamin most people associate with energy metabolism and cholesterol support — has produced a striking early result. In a small clinical trial, high-dose niacin was used alongside standard glioblastoma treatment. At the point of reporting, 82% of patients in the trial were still alive. For a cancer with this prognosis, that number stops you in your tracks.
Klara: It does. But I want to be careful here. This is a small trial. We don't yet have peer-reviewed, long-term survival data. The doses used are well above anything in a standard supplement — we're talking therapeutic levels that require medical supervision. Nobody should be reading this and reaching for their B3 capsules.
Marco: Agreed on the clinical caveats. But from a brand-building perspective, this is still significant. Cognitive health and longevity brands can legitimately reference this emerging science to build credibility around niacin as an ingredient — without making any health claims. Thought leadership content, science blogs, educational newsletters. That's the lane.
Klara: The lane is narrow though. Under EU regulation EC 1924/2006, implying a vitamin treats or prevents disease — even indirectly — is prohibited. Brands need to stay clearly on the right side of that line.
Marco: Noted. Now let's turn to our next story.
Klara: A new meta-analysis — that's a study pooling results from multiple trials — looks at whether omega-3 supplementation can help children with ADHD.
Klara: ADHD affects a significant share of children across Europe, and parents are actively looking for nutritional support alongside or instead of medication. The omega-3 space has long made broad "brain health" promises, but the evidence has been patchy. This study adds some much-needed precision.
Klara: Researchers analysed 16 clinical trials on omega-3 supplementation in children with ADHD. They found modest but real cognitive improvements. Crucially, those improvements showed up more clearly on cognitive performance tests than on behavioural outcomes. So we're talking about a specific, measurable benefit — not a sweeping transformation in how these children behave day-to-day.
Klara: From a science standpoint, "modest and context-dependent" matters enormously. This is not a cure. It's a meaningful signal from a well-constructed body of evidence. Under EC 1924/2006, brands cannot claim omega-3 treats or manages ADHD — full stop. What this research does support is carefully worded messaging around cognitive function, which already has EFSA-authorised health claims for DHA, the key omega-3 fatty acid.
Marco: And that's actually a commercial gift, if brands use it intelligently. Parents of children with ADHD are highly informed consumers. They read the studies. They spot overstatements immediately. A brand that communicates the nuance — "supports cognitive function, as shown in clinical research" — will land far better than one shouting miracle cure.
Klara: That's where I'd caution though. The distinction between cognitive performance on tests and real-world behavioural change is subtle. Marketing that blurs that line will face both regulatory scrutiny and a serious trust problem with exactly the audience they're trying to reach.
Marco: That's a fair tension. Right — let's move to our next story.
Marco: New research suggests mulberry compounds can reshape gut bacteria and influence how the body processes energy.
Marco: Gut health is still the most commercially active category across European supplement retail — from pharmacy shelves to dm and Holland & Barrett. The space is crowded, but it keeps growing because consumer demand keeps growing. The challenge for brands right now is differentiation. Most of the market is anchored to well-known ingredients like lactobacillus strains and inulin. Mulberry hasn't really entered that conversation yet.
Marco: This research changes that. Scientists found that specific compounds in mulberry can remodel the gut microbiome — the community of bacteria living in the digestive system — in ways that support both intestinal health and metabolic function. Metabolic function here means how efficiently the body manages things like blood sugar and energy use. Notably, certain combinations of mulberry-derived compounds produced stronger effects than individual compounds alone. That synergistic effect — where the combination outperforms the sum of its parts — is a direct signal for brands to think about proprietary blends rather than off-the-shelf single-ingredient formulations.
Klara: The science is promising, but I want to flag what we're working with. Microbiome research is advancing fast, and the synergy finding is intriguing. However, EFSA has approved very few health claims specifically for prebiotic botanical ingredients. Brands cannot claim mulberry reshapes the microbiome on a label without authorised substantiation. General gut health messaging is possible, but the regulatory headroom is tighter than the research might suggest.
Marco: I'd frame that differently. Early movers aren't selling the EFSA claim — they're building category authority through science communication and formulation credibility before the market commoditises this ingredient. That window doesn't stay open long.
Klara: True, though the science needs to mature before that story becomes fully defensible at shelf.
Marco: Let's move to our final story for today.
Klara: Saputo, one of the world's largest dairy processors, has just created a standalone ingredients division — and it tells us something important about where the protein market is heading.
Klara: Whey protein is a byproduct of cheese manufacturing. For decades, processors treated it as exactly that — a secondary output, sold as a commodity. What's changed is the scale of demand. Sports nutrition, high-protein functional foods, meal replacements — all of these categories have expanded significantly across European retail. Upstream suppliers are responding.
Klara: Saputo's decision elevates protein ingredients from a commodity line into a dedicated strategic business unit. That's not a minor reorganisational footnote. It signals that a major global processor is committing capital, focus, and commercial infrastructure specifically to meeting protein ingredient demand — which has direct consequences for brands that rely on whey supply.
Marco: From a procurement standpoint, this is the kind of structural shift that brand leaders should be tracking closely. When a supplier of this scale formalises a dedicated division, it typically means more sophisticated pricing mechanisms, tiered supplier relationships, and eventually, preferred access for larger or more strategically aligned buyers. Smaller brands risk being pushed down the queue.
Klara: I'd actually temper that slightly. More organised supply at scale could improve consistency and traceability — both of which matter enormously for quality assurance. A more professionalised ingredient supplier can be better for smaller brands too, if the documentation and specification standards improve across the board.
Marco: That's possible long-term. But in the near term, brands without locked-in supplier relationships are exposed. GLP-1 medications are already reshaping how consumers think about protein intake, accelerating demand further. Supply-chain security is becoming a genuine competitive advantage in this category — not just a logistics consideration.
Marco: If there's one thread running through today — it's that ingredient stories with real clinical weight are becoming the sharpest commercial differentiators in a crowded market.
Klara: But the science only protects you if your claims stay within what's actually been demonstrated — oversell it, and the credibility collapses fast.